MCID: ACR007
MIFTS: 65

Acromegaly malady

Categories: Rare diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Acromegaly

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 27GTR, 31ICD10 via Orphanet, 39MeSH, 40MESH via Orphanet, 45NCIt, 48NIH Rare Diseases, 50Novoseek, 54Orphanet, 62SNOMED-CT, 68UMLS, 69UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Acromegaly:

Name: Acromegaly 11 48 54 12 50 39 13 68
Growth Hormone Excess 48 27
Growth Hormone-Secreting Pituitary Adenoma 68
 
Somatotroph Adenoma 48
Pituitary Giant 48

Characteristics:

Orphanet epidemiological data:

54
acromegaly:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult

Classifications:



External Ids:

Disease Ontology11 DOID:2449
MeSH39 D000172
NCIt45 C84533
Orphanet54 ORPHA963
MESH via Orphanet40 D000172
UMLS via Orphanet69 C0001206
ICD10 via Orphanet31 E22.0

Summaries for Acromegaly

About this section
NIH Rare Diseases:48 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain. Acromegaly is usually treatable but when left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly. Last updated: 4/29/2011

MalaCards based summary: Acromegaly, also known as growth hormone excess, is related to pituitary adenoma, prolactin-secreting and lateral sclerosis, and has symptoms including tall stature, abnormality of the tongue and thick lower lip vermilion. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways are Growth hormone receptor signaling and Ovarian steroidogenesis. The drugs 2-bromoergocryptine mesylate and octreotide have been mentioned in the context of this disorder. Affiliated tissues include limb, pituitary and testes, and related mouse phenotypes are adipose tissue and integument.

Disease Ontology:11 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia:71 Acromegaly is a condition that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

About this section

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 281)
idRelated DiseaseScoreTop Affiliating Genes
1pituitary adenoma, prolactin-secreting30.7AIP, GHRH, GNAS, GPR101, IGF1, PRL
2lateral sclerosis29.7INS, POMC, PRL
3diabetes insipidus29.6GHRH, IGF1, INS, POMC, PRL
4postural hypotension29.3GH1, GNAS, IGF1, PRL, SST, SSTR5
5craniopharyngioma29.0GH1, GHRH, INS, POMC, PRL, TRH
6pheochromocytoma28.2MEN1, POMC, SST, SSTR1
7obesity27.5GHRH, GHRL, GNAS, IGF1, IGF2, IGFBP1
8pituitary adenoma, growth hormone-secreting11.9
9x-linked intellectual disability-acromegaly-hyperactivity syndrome11.8
10pituitary adenoma, growth hormone-secreting 211.5
11mccune-albright syndrome, somatic, mosaic10.8
12ossification of the posterior longitudinal ligament of the spine10.8
13spinal muscular atrophy type 1 with congenital bone fractures10.7IGF1, IGFBP3
14acyl-coa dehydrogenase, short-chain, deficiency of10.7GHR, IGF1
15als2-related disorders10.7AIP, GNAS
16pituitary deficiency due to rathke's pouch cysts10.7GH1, GHR, SST
17ovarian mucinous malignant adenofibroma10.7GH1, PRL, SST
18fumarate hydratase deficiency10.7GH1, GNAS, PRL
19seizures mental retardation hair dysplasia10.6IGF1, IGFBP3, INS
20diarrhea 3, secretory sodium, congenital, syndromic10.6IGF1, IGFBP3, INS
21lung large cell carcinoma10.6SST, SSTR2
22brachial plexus lesion10.6INS, SST
23pleural empyema10.6IGF1, INS, PRL
24hyperinsulinemic hypoglycemia, familial, 510.6IGF1, IGFBP3, INS
25genetic lipodystrophy10.6PRL, TRH
26brain angioma10.6POMC, SST
27petrous apex meningioma10.6INS, SST
28deep corneal vascularisation10.6GHRL, SST
29short bowel syndrome10.6IGF1, INS, SST
30strabismus10.6PRL, SST
31septicemic plague10.5IGF1, IGFBP3, PRL
32tropical sprue10.5GHRL, IGF1, SST
33echolalia10.5GNAS, PRL, TRH
34lymphedema10.5IGF1, INS, SST
35autoimmune oophoritis10.5GH1, POMC
36ossifying fibroma10.5SST, SSTR2, SSTR5
37hereditary koilonychia10.5GH1, GHRH
38lipid-rich carcinoma10.5POMC, PRL, SST
39repetitive motion disorders10.5INS, SST
40immune system organ benign neoplasm10.5IGF1, POMC, PRL
41dysthymic disorder10.5GHRL, INS, PRL
42growth retardation hydrocephaly lung hypoplasia10.5GH1, GHRH, IGF1, IGFBP3
43postpartum depression10.5INS, POMC, PRL
44hypertrichosis10.5IGF1, INS, SST
45loeffler endocarditis10.5POMC, PRL, SST
46nasopharyngeal disease10.5POMC, PRL, SST
4710.5GHRH, POMC, SST
48breast large cell neuroendocrine carcinoma10.4IGF1, IGFBP3
49diabetes mellitus, transient neonatal, 310.4IGF2, INS, SST
50splenic artery aneurysm10.4IGF1, IGF2, INS

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to acromegaly

Symptoms & Phenotypes for Acromegaly

About this section

Human phenotypes related to Acromegaly:

 64 54 (show all 70)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 tall stature64 54 hallmark (90%) Very frequent (99-80%) HP:0000098
2 abnormality of the tongue64 hallmark (90%) HP:0000157
3 thick lower lip vermilion64 54 hallmark (90%) Very frequent (99-80%) HP:0000179
4 coarse facial features64 54 hallmark (90%) Very frequent (99-80%) HP:0000280
5 full cheeks64 54 hallmark (90%) Very frequent (99-80%) HP:0000293
6 mandibular prognathia64 54 hallmark (90%) Very frequent (99-80%) HP:0000303
7 broad forehead64 54 hallmark (90%) Very frequent (99-80%) HP:0000337
8 abnormality of the nose64 hallmark (90%) HP:0000366
9 anterior hypopituitarism64 54 hallmark (90%) Very frequent (99-80%) HP:0000830
10 hyperhidrosis64 54 hallmark (90%) Very frequent (99-80%) HP:0000975
11 joint swelling64 54 hallmark (90%) Very frequent (99-80%) HP:0001386
12 broad foot64 54 hallmark (90%) Very frequent (99-80%) HP:0001769
13 deep plantar creases64 54 hallmark (90%) Very frequent (99-80%) HP:0001869
14 osteoarthritis64 54 hallmark (90%) Very frequent (99-80%) HP:0002758
15 arthralgia64 54 hallmark (90%) Very frequent (99-80%) HP:0002829
16 deep palmar crease64 54 hallmark (90%) Very frequent (99-80%) HP:0006191
17 macrodactyly of finger64 hallmark (90%) HP:0100746
18 abnormality of the menstrual cycle64 typical (50%) HP:0000140
19 abnormality of the teeth64 54 typical (50%) Frequent (79-30%) HP:0000164
20 synophrys64 54 typical (50%) Frequent (79-30%) HP:0000664
21 behavioral abnormality64 typical (50%) HP:0000708
22 diabetes mellitus64 54 typical (50%) Frequent (79-30%) HP:0000819
23 hypertension64 54 typical (50%) Frequent (79-30%) HP:0000822
24 abnormality of the fingernails64 54 typical (50%) Frequent (79-30%) HP:0001231
25 abnormality of the voice64 typical (50%) HP:0001608
26 frontal bossing64 54 typical (50%) Frequent (79-30%) HP:0002007
27 migraine64 54 typical (50%) Frequent (79-30%) HP:0002076
28 apnea64 typical (50%) HP:0002104
29 kyphosis64 54 typical (50%) Frequent (79-30%) HP:0002808
30 paresthesia64 54 typical (50%) Frequent (79-30%) HP:0003401
31 spinal canal stenosis64 54 typical (50%) Frequent (79-30%) HP:0003416
32 abnormality of the toenails64 54 typical (50%) Frequent (79-30%) HP:0008388
33 cerebral palsy64 54 typical (50%) Frequent (79-30%) HP:0100021
34 palpebral edema64 54 typical (50%) Frequent (79-30%) HP:0100540
35 neoplasm of the endocrine system64 typical (50%) HP:0100568
36 abnormality of reproductive system physiology64 54 occasional (7.5%) Occasional (29-5%) HP:0000080
37 acanthosis nigricans64 54 occasional (7.5%) Occasional (29-5%) HP:0000956
38 acne64 54 occasional (7.5%) Occasional (29-5%) HP:0001061
39 abnormality of the mitral valve64 occasional (7.5%) HP:0001633
40 hypertrophic cardiomyopathy64 54 occasional (7.5%) Occasional (29-5%) HP:0001639
41 reduced consciousness/confusion64 occasional (7.5%) HP:0004372
42 generalized hyperpigmentation64 54 occasional (7.5%) Occasional (29-5%) HP:0007440
43 abnormal renal physiology64 occasional (7.5%) HP:0012211
44 erectile abnormalities64 occasional (7.5%) HP:0100639
45 galactorrhea64 54 occasional (7.5%) Occasional (29-5%) HP:0100829
46 long penis54 Very frequent (99-80%)
47 macroglossia54 Very frequent (99-80%)
48 long face54 Very frequent (99-80%)
49 macrotia54 Very frequent (99-80%)
50 wide nose54 Very frequent (99-80%)
51 widely spaced teeth54 Frequent (79-30%)
52 depression54 Frequent (79-30%)
53 anxiety54 Frequent (79-30%)
54 impotence54 Occasional (29-5%)
55 abnormality of the endocrine system54 Very frequent (99-80%)
56 thickened skin54 Very frequent (99-80%)
57 large hands54 Very frequent (99-80%)
58 tapered finger54 Very frequent (99-80%)
59 hoarse voice54 Frequent (79-30%)
60 mitral regurgitation54 Occasional (29-5%)
61 generalized hirsutism54 Frequent (79-30%)
62 cortical diaphyseal thickening of the upper limbs54 Very frequent (99-80%)
63 macrodactyly54 Very frequent (99-80%)
64 sleep apnea54 Frequent (79-30%)
65 fatigue54 Very frequent (99-80%)
66 broad jaw54 Frequent (79-30%)
67 dysuria54 Occasional (29-5%)
68 dysmenorrhea54 Frequent (79-30%)
69 hypersomnia54 Occasional (29-5%)
70 pituitary prolactin cell adenoma54 Frequent (79-30%)

UMLS symptoms related to Acromegaly:


pseudothrombophlebitis, musculoskeletal stiffness, extremity contracture, trendelenburg's symptom, chest wall necrosis, musculoskeletal and connective tissue signs and symptoms nec, mass of lower limb, mass of upper limb, cushingoid facies

MGI Mouse Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053759.6GHR, GHRL, GNAS, IGF1, IGFBP3, INS
2MP:00107719.2AIP, GHR, GNAS, IGF1, IGF2, IGFBP3
3MP:00053859.1AIP, GHR, GNAS, IGF1, IGF2, INS
4MP:00053878.5GHR, GHRH, GNAS, IGF1, IGF2, IGFBP1
5MP:00053708.5AIP, GHR, GHRH, GNAS, IGF2, IGFBP1
6MP:00053868.3GHR, GHRL, GNAS, IGF2, IGFBP3, INS
7MP:00053788.2AIP, GHR, GHRH, GNAS, IGF1, IGF2
8MP:00053797.8AIP, GHR, GHRH, GHRL, GNAS, IGF1
9MP:00036317.1GHR, GHRH, GNAS, IGF1, IGF2, INS
10MP:00053766.8AIP, GHR, GHRH, GHRL, GNAS, IGF1

Drugs & Therapeutics for Acromegaly

About this section

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 94)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Octreotideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 121383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
2
SomatostatinapprovedPhase 4, Phase 3, Phase 2, Phase 122938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
3
lanreotideapprovedPhase 4, Phase 3, Phase 2, Phase 182108736-35-2
Synonyms:
Lanreotide
 
Lanreotide acetate
Somatuline Depot
4
CabergolineapprovedPhase 4, Phase 34681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
5
DopamineapprovedPhase 4, Phase 3, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6
MetforminapprovedPhase 41746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
7
LiraglutideapprovedPhase 4315204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
8
ZincapprovedPhase 422317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
9Antineoplastic Agents, HormonalPhase 4, Phase 3, Phase 2, Phase 15407
10AngiopeptinPhase 4, Phase 3, Phase 2, Phase 182
11Insulin, Globin ZincPhase 4, Phase 3, Phase 24523
12insulinPhase 4, Phase 3, Phase 24524
13Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 18109
14Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112778
15MitogensPhase 4, Phase 3, Phase 21526
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Phase 112767
17Complement Factor IPhase 4, Phase 335
18HormonesPhase 4, Phase 3, Phase 2, Phase 113979
19
LactitolPhase 4, Phase 3, Phase 1332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
20Hypoglycemic AgentsPhase 4, Phase 25733
21Liver ExtractsPhase 43868
22Autonomic AgentsPhase 4, Phase 2, Phase 39774
23Dopamine AgentsPhase 4, Phase 3, Phase 23759
24Antiparkinson AgentsPhase 4, Phase 31527
25Protective AgentsPhase 4, Phase 27190
26Dopamine agonistsPhase 4, Phase 3618
27Neurotransmitter AgentsPhase 4, Phase 3, Phase 217734
28Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 322776
29Sitagliptin PhosphatePhase 4416
30
protease inhibitorsPhase 45320
Synonyms:
 
protease inhibitors
31Dipeptidyl-Peptidase IV InhibitorsPhase 4846
32Pharmaceutical SolutionsPhase 47793
33IncretinsPhase 41537
34HIV Protease InhibitorsPhase 45319
35
Mannitolapproved, investigationalPhase 326869-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
36
Hydrocortisoneapproved, vet_approvedPhase 2, Phase 364050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
37
Lidocaineapproved, vet_approvedPhase 2, Phase 31226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
38
Epinephrineapproved, vet_approvedPhase 2, Phase 393351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
39Carboxymethylcellulose SodiumPhase 3172
40EdotreotidePhase 322
41RadiopharmaceuticalsPhase 3485
42Hydrocortisone 17-butyrate 21-propionatePhase 2, Phase 3640
43glucocorticoidsPhase 2, Phase 34920
44Respiratory System AgentsPhase 2, Phase 34818
45Epinephryl boratePhase 2, Phase 3933
46Vasoconstrictor AgentsPhase 2, Phase 32027
47RacepinephrinePhase 2, Phase 3933
48MydriaticsPhase 2, Phase 3763
49Hydrocortisone acetatePhase 2, Phase 3640
50Bronchodilator AgentsPhase 2, Phase 32856

Interventional clinical trials:

(show top 50)    (show all 143)
idNameStatusNCT IDPhase
1Effects of Sandostatin LAR® in AcromegalyUnknown statusNCT01424241Phase 4
2Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist PegvisomantUnknown statusNCT00552851Phase 4
3Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)Unknown statusNCT00915954Phase 4
4Preoperative Octreotide Treatment of AcromegalyCompletedNCT00521300Phase 4
5Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LARCompletedNCT00216398Phase 4
6Acute Application of Pegvisomant and Octreotide in AcromegalyCompletedNCT00595140Phase 4
7Lanreotide Autogel-120 mg as First-Line Treatment of AcromegalyCompletedNCT00627796Phase 4
8Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical TargetCompletedNCT01618513Phase 4
9Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant AcromegalyCompletedNCT00461149Phase 4
10Somatuline Autogel: Acromegaly Self/Partner Injection StudyCompletedNCT00149188Phase 4
11A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With AcromegalyCompletedNCT00068042Phase 4
12A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or OctreotideCompletedNCT00234520Phase 4
13Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic PatientsCompletedNCT01014793Phase 4
14Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient SatisfactionCompletedNCT00145405Phase 4
15Efficacy of Octreotide Acetate and Cabergoline in Patients With AcromegalyCompletedNCT00376064Phase 4
16A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.CompletedNCT01861717Phase 4
17Canadian Pegvisomant Compassionate Study In Acromegalic PatientsCompletedNCT00151437Phase 4
18Pegvisomant And Sandostatin LAR Combination StudyCompletedNCT00068029Phase 4
19Non Interventional Study For Patients Treated With Somavert®CompletedNCT00858143Phase 4
20Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic PatientsCompletedNCT01278342Phase 4
21Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic PatientsCompletedNCT00642720Phase 4
22Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic SubjectsCompletedNCT00701363Phase 4
23Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following SurgeryCompletedNCT00500227Phase 4
24Surgical Debulking of Pituitary AdenomasCompletedNCT01371643Phase 4
25Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From AcromegalyRecruitingNCT02115906Phase 4
26Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
27Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin AnaloguesRecruitingNCT02427295Phase 4
28Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
29Pasireotide LAR and Pegvisomant Study in AcromegalyActive, not recruitingNCT02668172Phase 4
30Octreotide Efficacy and Safety in First-line Acromegalic PatientsSuspendedNCT00171886Phase 4
31Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or MacroadenomasTerminatedNCT00242541Phase 4
32Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With AcromegalyCompletedNCT00225979Phase 3
33Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for AcromegalyCompletedNCT01412424Phase 3
34Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline AutogelCompletedNCT00447499Phase 3
35Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With AcromegalyCompletedNCT00499993Phase 3
36Long Term Study With B2036-PEGCompletedNCT00143416Phase 3
37Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active AcromegalyCompletedNCT00600886Phase 3
38Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled AcromegalyCompletedNCT00372697Phase 3
39Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With AcromegalyCompletedNCT00444873Phase 3
40Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic PatientsCompletedNCT00128232Phase 3
41Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With AcromegalyCompletedNCT00234572Phase 2, Phase 3
42Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00635765Phase 3
43Efficacy and Safety of C2L-OCT-01 PR in Acromegalic PatientsCompletedNCT00616551Phase 3
44Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaCompletedNCT00690898Phase 3
45A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 3
46Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic PatientsCompletedNCT00383708Phase 3
47Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCompletedNCT00210457Phase 3
48Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in AcromegalyRecruitingNCT02685709Phase 3
49Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin AnaloguesRecruitingNCT02354508Phase 3
50Ga-68-DOTATOC -PET in the Management of Pituitary TumoursRecruitingNCT02419664Phase 3

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

About this section

Genetic tests related to Acromegaly:

id Genetic test Affiliating Genes
1 Growth Hormone Excess27

Anatomical Context for Acromegaly

About this section

MalaCards organs/tissues related to Acromegaly:

36
Pituitary, Testes, Bone, Skin, Thyroid, Heart, Liver

FMA organs/tissues related to Acromegaly:

17
Limb

Publications for Acromegaly

About this section

Articles related to Acromegaly:

(show top 50)    (show all 1476)
idTitleAuthorsYear
1
Diagnosis of acromegaly: black, whitea8 (27982196)
nd sometimes
2
Cases:-Sarcoma of Cervix. Primary Carcinoma of Fallopian Tube. Primary Sarcoma of Fallopian Tube. Grossesse Extramembraneuse. An Unusual Ectopic Pregnancy. Chocolate Cysts of the Ovary (Ovarian Endometriosis) and Pregnancy: A Report of Two Cases Occurring in Sisters. Acromegaly with Pregnancy. AnA (20917467)
mia in a Rhe
3
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. (27932528)
2017
4
Bone Material Strength index as measured by impact microindentation is altered in patients with acromegaly. (28077497)
2017
5
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. (27896545)
2017
6
Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. (27932529)
2017
7
Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature. (27913611)
2017
8
Assessment of Nasal Carriage of Staphylococcus Aureus and Axillar Flora in Patients With Acromegaly. (28060097)
2017
9
Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. (27910111)
2017
10
Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. (28042644)
2017
11
Communication practices and awareness of resources for acromegaly patients among endocrinologists. (28008238)
2016
12
Childhood acromegaly due to X-linked acrogigantism: long term follow-up. (27631333)
2016
13
Mortality in acromegaly: a twenty-year follow-up study. (27185871)
2016
14
Long-Term Remission of Acromegaly after Octreotide withdrawal is an Uncommon and Frequently Unsustainable Event. (27161443)
2016
15
The possible role of mRNA expression changes of GH/IGF-1/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly. (27070751)
2016
16
Adiponectin and Cardiac Hypertrophy in Acromegaly. (27629732)
2016
17
Acromegaly in sleep apnoea patients: a large observational study of 755 patients. (27660510)
2016
18
Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly. (28042650)
2016
19
Combination of Klinefelter Syndrome and Acromegaly: A Rare Case Report. (27124035)
2016
20
Ectopic Acromegaly Arising from a Pituitary Adenoma within the Bony Intersphenoid Septum of a Patient with Empty Sella Syndrome. (27468406)
2016
21
Successful treatment of residual pituitary adenoma in persistent acromegaly following localisation by 11C-methionine PET co-registered with MRI. (27562400)
2016
22
Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naA^ve acromegaly patients: a prospective study at baseline and after 1A year of somatostatin analogs treatment. (27591859)
2016
23
Increased Population Risk of AIP-related Acromegaly and Gigantism in Ireland. (27650164)
2016
24
Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. (27153851)
2016
25
Implementing a screening program for acromegaly in Latin America: necessity versus feasibility. (27130456)
2016
26
The role of combination medical therapy in the treatment of acromegaly. (27522663)
2016
27
Leptin Receptor Gene Polymorphism may Affect Subclinical Atherosclerosis in Patients with Acromegaly. (27563428)
2016
28
Late presentation of acromegaly in medically controlled prolactinoma patients. (27855229)
2016
29
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. (27039081)
2016
30
Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis. (27586125)
2016
31
DISEASE ACTIVITY AND LIFESTYLE INFLUENCE COMORBIDITIES AND CARDIOVASCULAR EVENTS IN PATIENTS WITH ACROMEGALY. (27528501)
2016
32
Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. (27055553)
2016
33
Cabergoline in acromegaly. (28025719)
2016
34
Patients with Acromegaly Presenting with Colon Cancer: A Case Series. (28025627)
2016
35
Pasireotide (SIGNIFOR) in acromegaly. After treatment failure: better than pegvisomant. (27042726)
2016
36
General health status and intelligence scores of children of mothers with acromegaly do not differ from those of healthy mothers. (27033692)
2016
37
An acromegaly-induced cardiomyopathy mimicking amyloidosis: (Manifestation of acromegaly-induced-cardiomyopathy). (27111161)
2016
38
Acromegaly in a patient with a pulmonary neuroendocrine tumor: case report and review of current literature. (27349224)
2016
39
Auditory changes in acromegaly. (28035526)
2016
40
Role of ambulatory blood pressure monitoring in patients with acromegaly. (27153464)
2016
41
Pregnancy and acromegaly. (27568329)
2016
42
Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naA^ve active acromegaly. (27117887)
2016
43
INCIDENCE AND PREVALENCE OF ACROMEGALY IN THE UNITED STATES: A CLAIMS-BASED ANALYSIS. (27540880)
2016
44
Elevated IGF-1 with GH suppression after an oral glucose overload: incipient acromegaly or false-positive IGF-1? (27982199)
2016
45
Coexistence of acromegaly with dural arteriovenous fistula of the cavernous sinus. (27194169)
2016
46
Acromegaly presenting as cutis verticis gyrata. (26873450)
2016
47
MANAGEMENT OF ENDOCRINE DISEASE: ACROMEGALY AND CANCER: AN OLD DEBATE REVISITED. (27089890)
2016
48
Complications of acromegaly: thyroid and colon. (27631334)
2016
49
High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. (27601020)
2016
50
Epidemiology of acromegaly in Ecuador. (27158065)
2016

Variations for Acromegaly

About this section

Clinvar genetic disease variations for Acromegaly:

5
id Gene Variation Type Significance SNP ID Assembly Location
1GNASNM_000516.5(GNAS): c.601C> T (p.Arg201Cys)SNVPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
2GNASNM_000516.5(GNAS): c.602G> A (p.Arg201His)SNVPathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
3GNASNM_000516.5(GNAS): c.680A> G (p.Gln227Arg)SNVPathogenicrs121913494GRCh37Chr 20, 57484596: 57484596
4GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)SNVPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
5AIPNM_003977.3(AIP): c.40C> T (p.Gln14Ter)SNVPathogenicrs104894194GRCh37Chr 11, 67250669: 67250669

Expression for genes affiliated with Acromegaly

About this section
Search GEO for disease gene expression data for Acromegaly.

Pathways for genes affiliated with Acromegaly

About this section

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 16)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.9GH1, GHR, PRL
29.9GNAS, IGF1, INS
39.8IGF1, IGFBP3, INS
49.7IGF1, IGF2, INS
59.5GH1, GHR, IGF1, IGF2
69.4GH1, GHR, IGF1, INS, PRL
79.4IGF1, IGF2, IGFBP1, IGFBP3
8
Show member pathways
9.4IGF1, IGF2, IGFBP1, IGFBP3
99.3GH1, GHRH, GNAS, IGF1, IGF2
10
Show member pathways
9.1GH1, GHRL, IGF1, INS, POMC
11
Show member pathways
9.1GH1, GHRH, GNAS, IGF1, IGF2, INS
12
Show member pathways
8.9GHRL, GNAS, SSTR1, SSTR2, SSTR5
13
Show member pathways
8.7GH1, GHR, GHRH, GNAS, IGF1, IGF2
14
Show member pathways
8.0GH1, GHRL, IGF1, IGF2, IGFBP1, IGFBP3
15
Show member pathways
7.3GH1, GHR, GHRH, GHRL, GNAS, POMC
16
Show member pathways
6.2GH1, GHR, GHRH, GHRL, GNAS, IGF1

GO Terms for genes affiliated with Acromegaly

About this section

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor binding protein complexGO:001694210.4IGF1, IGFBP3
2insulin-like growth factor ternary complexGO:004256710.3IGF1, IGFBP3
3secretory granule lumenGO:00347749.5GHRL, INS, POMC
4extracellular spaceGO:00056157.9GH1, GHR, GHRH, GHRL, IGF1, IGF2
5extracellular regionGO:00055767.9GH1, GHR, GHRH, GHRL, IGF1, IGF2

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 33)
idNameGO IDScoreTop Affiliating Genes
1insulin-like growth factor receptor signaling pathwayGO:004800910.8GHR, IGF1
2growth hormone receptor signaling pathwayGO:006039610.8GH1, GHR
3positive regulation of glycolytic processGO:004582110.7IGF1, INS
4negative regulation of feeding behaviorGO:200025210.7INS, TRH
5JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.6GH1, GHR, PRL
6growth hormone secretionGO:003025210.6GHRH, GHRL
7positive regulation of JAK-STAT cascadeGO:004642710.5GH1, GHR, PRL
8positive regulation of insulin receptor signaling pathwayGO:004662810.5IGF2, INS
9positive regulation of growth hormone secretionGO:006012410.5GHRH, GHRL
10regulation of insulin-like growth factor receptor signaling pathwayGO:004356710.5IGFBP1, IGFBP3
11positive regulation of tyrosine phosphorylation of Stat5 proteinGO:004252310.4GH1, GHR, IGF1
12female pregnancyGO:000756510.4IGF1, IGF2, PRL
13positive regulation of phosphatidylinositol 3-kinase signalingGO:001406810.4GH1, IGF1, INS
14regulation of multicellular organism growthGO:004001410.4GHR, IGF1, PRL
15hormone-mediated signaling pathwayGO:000975510.3GHR, GHRL, TRH
16positive regulation of glycogen biosynthetic processGO:004572510.3IGF1, IGF2, INS
17positive regulation of insulin-like growth factor receptor signaling pathwayGO:004356810.3GH1, GHRH, IGF1, IGFBP3
18positive regulation of mitotic nuclear divisionGO:004584010.3IGF1, IGF2, INS
19cellular response to estradiol stimulusGO:007139210.3IGF1, SSTR1, SSTR2
20digestionGO:000758610.3SST, SSTR1, SSTR2
21insulin receptor signaling pathwayGO:000828610.2IGF2, IGFBP1, INS
22G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerGO:000718710.2SSTR1, SSTR2, SSTR5
23glucose metabolic processGO:000600610.1GHRL, IGF2, INS
24neuropeptide signaling pathwayGO:000721810.1POMC, SSTR1, SSTR2
25positive regulation of multicellular organism growthGO:004001810.1GH1, GHR, GHRH, GHRL
26positive regulation of MAPK cascadeGO:004341010.1IGF1, IGF2, IGFBP3, INS
27chemical synaptic transmissionGO:000726810.0SST, SSTR1, SSTR2, SSTR5
28positive regulation of peptidyl-tyrosine phosphorylationGO:00507319.9GH1, GHR, IGF1, IGF2, INS
29cellular protein metabolic processGO:00442679.6IGF1, IGF2, IGFBP1, IGFBP3, INS, PRL
30response to nutrientGO:00075849.5IGF1, SST, SSTR1, SSTR2
31somatostatin signaling pathwayGO:00381709.5SSTR1, SSTR2, SSTR5
32negative regulation of cell proliferationGO:00082859.4IGFBP3, MEN1, SST, SSTR1, SSTR2, SSTR5
33cell-cell signalingGO:00072679.1GHRH, GPR101, INS, POMC, SST, SSTR1

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1growth hormone-releasing hormone activityGO:001660810.4GHRH, GHRL
2insulin-like growth factor I bindingGO:003199410.4IGFBP1, IGFBP3
3insulin-like growth factor II bindingGO:003199510.4IGFBP1, IGFBP3
4prolactin receptor bindingGO:000514810.2GH1, PRL
5insulin receptor bindingGO:000515810.1IGF1, IGF2, INS
6insulin-like growth factor receptor bindingGO:00051599.9GNAS, IGF1, IGF2, INS
7neuropeptide bindingGO:00429239.6SSTR1, SSTR2, SSTR5
8somatostatin receptor activityGO:00049949.5SSTR1, SSTR2, SSTR5
9hormone activityGO:00051798.9GH1, GHRL, IGF1, IGF2, INS, POMC

Sources for Acromegaly

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet